| Nome |
# |
|
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study, file dfd1c04d-a2e9-0799-e053-6605fe0a8ddb
|
20
|
|
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management, file dfd1c04d-74c5-0799-e053-6605fe0a8ddb
|
10
|
|
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry, file dfd1c04d-c45b-0799-e053-6605fe0a8ddb
|
9
|
|
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease, file dfd1c04d-bdfa-0799-e053-6605fe0a8ddb
|
8
|
|
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes, file dfd1c04d-7000-0799-e053-6605fe0a8ddb
|
7
|
|
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention, file 414f35e6-04c3-4410-8c80-e45f4627fb6c
|
6
|
|
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial, file dfd1c04d-088f-0799-e053-6605fe0a8ddb
|
6
|
|
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome, file dfd1c04d-861f-0799-e053-6605fe0a8ddb
|
6
|
|
Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria, file dfd1c04d-ab87-0799-e053-6605fe0a8ddb
|
6
|
|
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies, file dfd1c04d-b5b3-0799-e053-6605fe0a8ddb
|
6
|
|
Prediction of radial crossover in acute coronary syndromes: Derivation and validation of the MATRIX score, file dfd1c04d-cc67-0799-e053-6605fe0a8ddb
|
6
|
|
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence, file dfd1c04d-e506-0799-e053-6605fe0a8ddb
|
6
|
|
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry), file dfd1c04d-f170-0799-e053-6605fe0a8ddb
|
6
|
|
Validation of high bleeding risk criteria and definition as proposed by the academic research consortiumfor high bleeding risk, file dfd1c04d-731a-0799-e053-6605fe0a8ddb
|
5
|
|
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity, file dfd1c04d-7700-0799-e053-6605fe0a8ddb
|
5
|
|
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial, file dfd1c04d-7d75-0799-e053-6605fe0a8ddb
|
5
|
|
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia, file dfd1c04d-c0d2-0799-e053-6605fe0a8ddb
|
5
|
|
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition, file dfd1c04d-e4f2-0799-e053-6605fe0a8ddb
|
5
|
|
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY, file dfd1c04d-f0c6-0799-e053-6605fe0a8ddb
|
5
|
|
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry, file dfd1c04d-feca-0799-e053-6605fe0a8ddb
|
5
|
|
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study, file a2ef4b41-7e63-445f-9c62-78fe9004b140
|
4
|
|
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study, file dfd1c04d-39c6-0799-e053-6605fe0a8ddb
|
4
|
|
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination, file dfd1c04d-710a-0799-e053-6605fe0a8ddb
|
4
|
|
Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry, file dfd1c04d-7704-0799-e053-6605fe0a8ddb
|
4
|
|
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy, file dfd1c04d-b5a9-0799-e053-6605fe0a8ddb
|
4
|
|
Are we ready for a gender-specific approach in interventional cardiology?, file dfd1c04d-e53e-0799-e053-6605fe0a8ddb
|
4
|
|
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience, file dfd1c04b-e511-0799-e053-6605fe0a8ddb
|
3
|
|
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)", file dfd1c04c-185e-0799-e053-6605fe0a8ddb
|
3
|
|
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?, file dfd1c04c-36cb-0799-e053-6605fe0a8ddb
|
3
|
|
Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis, file dfd1c04c-372e-0799-e053-6605fe0a8ddb
|
3
|
|
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease, file dfd1c04d-40dc-0799-e053-6605fe0a8ddb
|
3
|
|
Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology, file dfd1c04d-7316-0799-e053-6605fe0a8ddb
|
3
|
|
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve, file dfd1c04d-a630-0799-e053-6605fe0a8ddb
|
3
|
|
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects, file dfd1c04d-b330-0799-e053-6605fe0a8ddb
|
3
|
|
[Evaluation and percutaneous treatment of severely calcified coronary lesions], file dfd1c04d-b79b-0799-e053-6605fe0a8ddb
|
3
|
|
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk, file dfd1c04d-d6d0-0799-e053-6605fe0a8ddb
|
3
|
|
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest, file dfd1c04d-d77a-0799-e053-6605fe0a8ddb
|
3
|
|
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal, file dfd1c04d-d7f6-0799-e053-6605fe0a8ddb
|
3
|
|
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial, file dfd1c04d-ebb1-0799-e053-6605fe0a8ddb
|
3
|
|
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team, file dfd1c04d-f432-0799-e053-6605fe0a8ddb
|
3
|
|
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial, file dfd1c04d-fc08-0799-e053-6605fe0a8ddb
|
3
|
|
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry, file ef6d6c5d-480f-45ed-a7df-adc263f91fcf
|
3
|
|
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention, file 8b703d8a-5e23-4d1f-9384-50a4a8d232e8
|
2
|
|
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry, file af080beb-718e-4b93-8264-c17fd45d8b3c
|
2
|
|
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology, file bb104d05-bf9c-4630-937a-f74b07366b36
|
2
|
|
[The COMPASS study], file dfd1c04b-dc93-0799-e053-6605fe0a8ddb
|
2
|
|
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy?, file dfd1c04b-e1ba-0799-e053-6605fe0a8ddb
|
2
|
|
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience, file dfd1c04b-eff5-0799-e053-6605fe0a8ddb
|
2
|
|
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment, file dfd1c04c-7664-0799-e053-6605fe0a8ddb
|
2
|
|
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients, file dfd1c04c-a117-0799-e053-6605fe0a8ddb
|
2
|
|
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy, file dfd1c04c-e958-0799-e053-6605fe0a8ddb
|
2
|
|
Cognitive Function in a Randomized Trial of Evolocumab, file dfd1c04d-048e-0799-e053-6605fe0a8ddb
|
2
|
|
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team, file dfd1c04d-9de4-0799-e053-6605fe0a8ddb
|
2
|
|
Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment, file dfd1c04d-bd1f-0799-e053-6605fe0a8ddb
|
2
|
|
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease, file dfd1c04d-c0c1-0799-e053-6605fe0a8ddb
|
2
|
|
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial, file dfd1c04d-d319-0799-e053-6605fe0a8ddb
|
2
|
|
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry, file dfd1c04d-d5e4-0799-e053-6605fe0a8ddb
|
2
|
|
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy, file dfd1c04d-d778-0799-e053-6605fe0a8ddb
|
2
|
|
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty, file dfd1c04d-dd15-0799-e053-6605fe0a8ddb
|
2
|
|
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials, file dfd1c04d-f958-0799-e053-6605fe0a8ddb
|
2
|
|
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial, file dfd1c04d-fecc-0799-e053-6605fe0a8ddb
|
2
|
|
Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More?, file 851ee083-877e-4fed-8e72-22ea000a895c
|
1
|
|
From Femoral to Radial Approach in Coronary Intervention: Review of the Literature and 6 Years Single-Center Experience, file dfd1c04b-794c-0799-e053-6605fe0a8ddb
|
1
|
|
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement, file dfd1c04b-9719-0799-e053-6605fe0a8ddb
|
1
|
|
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications, file dfd1c04b-b28c-0799-e053-6605fe0a8ddb
|
1
|
|
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies, file dfd1c04b-dc9b-0799-e053-6605fe0a8ddb
|
1
|
|
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience, file dfd1c04b-e38d-0799-e053-6605fe0a8ddb
|
1
|
|
Letter by Calabro and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials", file dfd1c04b-eadb-0799-e053-6605fe0a8ddb
|
1
|
|
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry, file dfd1c04c-1867-0799-e053-6605fe0a8ddb
|
1
|
|
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines, file dfd1c04c-2ca6-0799-e053-6605fe0a8ddb
|
1
|
|
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition, file dfd1c04c-e7bf-0799-e053-6605fe0a8ddb
|
1
|
|
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?, file dfd1c04c-fde3-0799-e053-6605fe0a8ddb
|
1
|
|
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up, file dfd1c04d-03cc-0799-e053-6605fe0a8ddb
|
1
|
|
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study, file dfd1c04d-0434-0799-e053-6605fe0a8ddb
|
1
|
|
Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome, file dfd1c04d-083c-0799-e053-6605fe0a8ddb
|
1
|
|
Event recurrence after myocardial infarction: Prediction is very difficult, especially about the future, file dfd1c04d-1028-0799-e053-6605fe0a8ddb
|
1
|
|
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018), file dfd1c04d-10f0-0799-e053-6605fe0a8ddb
|
1
|
|
Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology, file dfd1c04d-7317-0799-e053-6605fe0a8ddb
|
1
|
|
Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: Dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del gruppo di studio aterosclerosi, trombosi e biologia vascolare, file dfd1c04d-7d77-0799-e053-6605fe0a8ddb
|
1
|
|
No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI, file dfd1c04d-7d79-0799-e053-6605fe0a8ddb
|
1
|
|
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial, file dfd1c04d-7de9-0799-e053-6605fe0a8ddb
|
1
|
|
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial, file dfd1c04d-9f2b-0799-e053-6605fe0a8ddb
|
1
|
|
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry, file dfd1c04d-a30d-0799-e053-6605fe0a8ddb
|
1
|
|
A call for action in bleeding prevention, file dfd1c04d-a5a7-0799-e053-6605fe0a8ddb
|
1
|
|
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence, file dfd1c04d-b26c-0799-e053-6605fe0a8ddb
|
1
|
|
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?, file dfd1c04d-cd69-0799-e053-6605fe0a8ddb
|
1
|
|
Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter, file dfd1c04d-d652-0799-e053-6605fe0a8ddb
|
1
|
|
The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury, file dfd1c04d-d693-0799-e053-6605fe0a8ddb
|
1
|
|
Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise, file dfd1c04d-d6c1-0799-e053-6605fe0a8ddb
|
1
|
|
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism, file dfd1c04d-d73a-0799-e053-6605fe0a8ddb
|
1
|
|
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes, file dfd1c04d-e508-0799-e053-6605fe0a8ddb
|
1
|
|
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy, file dfd1c04d-e539-0799-e053-6605fe0a8ddb
|
1
|
|
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores, file dfd1c04d-e5d7-0799-e053-6605fe0a8ddb
|
1
|
|
Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome, file dfd1c04d-e6bf-0799-e053-6605fe0a8ddb
|
1
|
|
Myocardial Infarction with and without ST-segment Elevation: a Contemporary Reappraisal of Similarities and Differences, file dfd1c04d-f0dd-0799-e053-6605fe0a8ddb
|
1
|
|
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease, file dfd1c04d-f2c2-0799-e053-6605fe0a8ddb
|
1
|
|
Natural history of left ventricular hypertrophy in infants of diabetic mothers, file dfd1c04d-fa4f-0799-e053-6605fe0a8ddb
|
1
|
|
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events, file dfd1c04d-fc07-0799-e053-6605fe0a8ddb
|
1
|
|
Balancing Benefits and Risks of Oral Antiplatelet Strategies in patients With Coronary Artery Diseases: An Evolving Issue, file ff55808d-0a7d-415e-abd7-b96a687e723a
|
1
|
| Totale |
285 |